Paratek Pharmaceuticals
Biopharmaceutical company focused on developing and commercializing novel antibiotics to combat serious bacterial infections, including those caused by antibiotic-resistant pathogens.
Location
Boston, Massachusetts, USA
Founded
1996
Investors
1
Categories
pharmaceuticals, antibiotics, infectious-disease, antimicrobial-resistance
Notes
Paratek Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel antibiotics for serious bacterial infections. The company's lead product, NUZYRA (omadacycline), is an aminomethylcycline antibiotic designed to overcome common bacterial resistance mechanisms.
Paratek addresses the critical public health challenge of antimicrobial resistance by developing new antibiotics active against resistant pathogens.
Team
- Evan Loh, M.D. - Chairman & Chief Executive Officer
- LinkedIn: linkedin.com/in/evanloh
- Adam Woodrow - Chief Commercial Officer
Additional Research Findings
- Founded in 1996 in Boston, Massachusetts
- Listed on NASDAQ (ticker: PRTK)
- Portfolio company of Polaris Partners
- Lead product NUZYRA (omadacycline) - approved antibiotic
- Focus on antimicrobial resistance (AMR) crisis
- FDA approved for CABP and ABSSSI indications
- Also developing SEYSARA for acne treatment
- Critical player in addressing antibiotic resistance
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |